Skip to main content

Table 1 Comparison of clinical characteristics between training and testing groups

From: MRI-based radiomics value for predicting the survival of patients with locally advanced cervical squamous cell cancer treated with concurrent chemoradiotherapy

Parameters

Training (n = 128)

Testing (n = 57)

P-value

Age (years, mean ± SD)

52.83 ± 8.76

52.63 ± 9.11

0.891

BMI (kg/m2, mean ± SD)

24.80 ± 3.44

24.63 ± 3.78

0.757

SCC-Ag (ng/mL, mean ± SD)

11.90 ± 22.20

11.02 ± 17.99

0.792

Tumor grade (%)

  

0.062

Low-grade (well/moderately differentiated)

81 (63.3%)

44 (77.2%)

 

High-grade (poorly differentiated)

47 (36.7%)

13 (22.8%)

 

T stage (%)

  

0.435

  T2

98 (76.6%)

39 (68.4%)

 

  T3

25 (19.5%)

16 (28.1%)

 

  T4

5 (3.9%)

2 (3.5%)

 

2018 FIGO stage (%)

  

0.928

  II

64 (50.0%)

27 (47.4%)

 

  III

59 (46.1%)

28 (49.1%)

 

  IVA

5 (3.9%)

2 (3.5%)

 

Tumor maximum-diameter (cm, mean ± SD)

4.49 ± 1.13

4.33 ± 1.35

0.400

LNM position (%)

  

0.906

  Negative

74 (57.8%)

31 (54.4%)

 

  Pelvic LNM

40 (31.3%)

19 (33.3%)

 

  Para-aortic LNM

14 (10.9%)

7 (12.3%)

 

LNM number (%)

  

0.813

  0

74 (57.8%)

31 (54.4%)

 

  ≤2

24 (18.8%)

13 (22.8%)

 

  >2

30 (23.4%)

13 (22.8%)

 
  1. SD Standard deviation, BMI Body mass index, SCC-Ag Serum levels of squamous cell carcinoma antigen, FIGO Federation of Gynecology and Obstetrics, LNM Lymph node metastasis.